These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

334 related articles for article (PubMed ID: 11746533)

  • 1. Donor lymphocyte apheresis for adoptive immunotherapy compared with blood stem cell apheresis.
    Körbling M; Giralt S; Khouri I; Mirza N; Donato M; Anderlini P; Fischer H; Andreeff M; McMannis J; Champlin R
    J Clin Apher; 2001; 16(2):82-7. PubMed ID: 11746533
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The impact of granulocyte colony stimulating factor at content of donor lymphocytes collected for cellular immunotherapy.
    Arat M; Arslan O; Gürman G; Dalva K; Ozcan M; Uğur A; Ilhan O
    Transfus Apher Sci; 2004 Feb; 30(1):9-15. PubMed ID: 14746816
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Allogeneic blood stem cell transplantation: peripheralization and yield of donor-derived primitive hematopoietic progenitor cells (CD34+ Thy-1dim) and lymphoid subsets, and possible predictors of engraftment and graft-versus-host disease.
    Körbling M; Huh YO; Durett A; Mirza N; Miller P; Engel H; Anderlini P; van Besien K; Andreeff M; Przepiorka D; Deisseroth AB; Champlin RE
    Blood; 1995 Oct; 86(7):2842-8. PubMed ID: 7545476
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High-versus standard-dose filgrastim (rhG-CSF) for mobilization of peripheral-blood progenitor cells from allogeneic donors and CD34(+) immunoselection.
    Engelhardt M; Bertz H; Afting M; Waller CF; Finke J
    J Clin Oncol; 1999 Jul; 17(7):2160-72. PubMed ID: 10561272
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Analysis of stem cell apheresis products using intermediate-dose filgrastim plus large volume apheresis for allogeneic transplantation.
    Engelhardt M; Bertz H; Wäsch R; Finke J
    Ann Hematol; 2001 Apr; 80(4):201-8. PubMed ID: 11401085
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of the content and subpopulations of CD3 and CD34 positive cells in bone marrow harvests and G-CSF-mobilized peripheral blood leukapheresis products from healthy adult donors.
    Hassan HT; Stockschläder M; Schleimer B; Krüger W; Zander AR
    Transpl Immunol; 1996 Dec; 4(4):319-23. PubMed ID: 8972563
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Delayed effects of rhG-CSF mobilization treatment and apheresis on circulating CD34+ and CD34+ Thy-1dim CD38- progenitor cells, and lymphoid subsets in normal stem cell donors for allogeneic transplantation.
    Körbling M; Anderlini P; Durett A; Maadani F; Bojko P; Seong D; Giralt S; Khouri I; Andersson B; Mehra R; vanBesien K; Mirza N; Przepiorka D; Champlin R
    Bone Marrow Transplant; 1996 Dec; 18(6):1073-9. PubMed ID: 8971375
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effect of G-CSF on lymphocyte subsets and CD34+ cells in allogeneic stem cell transplantation.
    Gürman G; Dilek I; Arslan O; Arat M; Beksaç M; Ilhan O; Ozcan M; Akan H; Dalva K; Konuk N; Uysal A; Koç H
    Transfus Apher Sci; 2001 Feb; 24(1):23-8. PubMed ID: 11515607
    [TBL] [Abstract][Full Text] [Related]  

  • 9. rhG-CSF in healthy donors: mobilization of peripheral hemopoietic progenitors and effect on peripheral blood leukocytes.
    Sica S; Rutella S; Di Mario A; Salutari P; Rumi C; Ortu la Barbera E; Etuk B; Menichella G; D'Onofrio G; Leone G
    J Hematother; 1996 Aug; 5(4):391-7. PubMed ID: 8877714
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prophylactic growth factor-primed donor lymphocyte infusion using cells reserved at the time of transplantation after allogeneic peripheral blood stem cell transplantation in patients with high-risk hematologic malignancies.
    Sohn SK; Jung JT; Kim DH; Lee NY; Seo KW; Chae YS; Park SW; Kim JG; Suh JS; Lee KB
    Cancer; 2002 Jan; 94(1):18-24. PubMed ID: 11815956
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Allogeneic blood stem cell transplantation: considerations for donors.
    Anderlini P; Körbling M; Dale D; Gratwohl A; Schmitz N; Stroncek D; Howe C; Leitman S; Horowitz M; Gluckman E; Rowley S; Przepiorka D; Champlin R
    Blood; 1997 Aug; 90(3):903-8. PubMed ID: 9242518
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mobilization and collection of PBSC in healthy donors: comparison between two schemes of rhG-CSF administration.
    Majolino I; Scimé R; Vasta S; Cavallaro AM; Fiandaca T; Indovina A; Catania P; Santoro A
    Eur J Haematol; 1996 Sep; 57(3):214-21. PubMed ID: 8898925
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Soluble adhesion molecules (sICAM-1, sL-Selectin, sE-Selectin, sCD44) in healthy allogenic peripheral stem-cell donors primed with recombinant G-CSF.
    Arslan O; Akan H; Arat M; Dalva K; Ozcan M; Gürman G; Ilhan O; Konuk N; Beksaç M; Uysal A; Koç H
    Cytotherapy; 2000; 2(4):259-65. PubMed ID: 12042035
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Collection of hematopoietic progenitor cells from healthy donors].
    Bojanić I; Cepulić BG; Mazić S
    Acta Med Croatica; 2009 Jun; 63(3):237-44. PubMed ID: 19827352
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Harvesting and enrichment of hematopoietic progenitor cells mobilized into the peripheral blood of normal donors by granulocyte-macrophage colony-stimulating factor (GM-CSF) or G-CSF: potential role in allogeneic marrow transplantation.
    Lane TA; Law P; Maruyama M; Young D; Burgess J; Mullen M; Mealiffe M; Terstappen LW; Hardwick A; Moubayed M
    Blood; 1995 Jan; 85(1):275-82. PubMed ID: 7528570
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mobilization of hematopoietic progenitor cells with paclitaxel (taxol) as a single chemotheraupetic agent, associated with rhG-CSF.
    Gómez-Espuch J; Moraleda JM; Ortuño F; Lozano ML; Ayala F; Vallejo C; de Arriba F; Vicente V
    Bone Marrow Transplant; 2000 Feb; 25(3):231-5. PubMed ID: 10673692
    [TBL] [Abstract][Full Text] [Related]  

  • 17. GM-CSF-based mobilization effect in normal healthy donors for allogeneic peripheral blood stem cell transplantation.
    Sohn SK; Kim JG; Seo KW; Chae YS; Jung JT; Suh JS; Lee KB
    Bone Marrow Transplant; 2002 Jul; 30(2):81-6. PubMed ID: 12132046
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Myelopoietin, a chimeric agonist of human interleukin 3 and granulocyte colony-stimulating factor receptors, mobilizes CD34+ cells that rapidly engraft lethally x-irradiated nonhuman primates.
    MacVittie TJ; Farese AM; Davis TA; Lind LB; McKearn JP
    Exp Hematol; 1999 Oct; 27(10):1557-68. PubMed ID: 10517498
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rapid engraftment after allogeneic transplantation of density-enriched peripheral blood CD34+ cells in patients with advanced hematologic malignancies.
    Cao TM; Kusnierz-Glaz C; Valone F; Stockerl-Goldstein KE; Hu WW; Johnston L; Blume KG; Strober S; Negrin RS
    Cancer; 2001 Jun; 91(12):2205-13. PubMed ID: 11413507
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CD34+ cell mobilization for allogeneic progenitor cell transplantation: efficacy of a short course of G-CSF.
    de Fabritiis P; Iori AP; Mengarelli A; Gozzer M; Ferrazza G; De Propris MS; Romano A; Arcese W
    Transfusion; 2001 Feb; 41(2):190-5. PubMed ID: 11239221
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.